Equites Radar

LMRI · Lumexa Imaging Holdings, Inc.

Medical DevicesUnited StatesAnalyst view: Strong Buy

$11.49

+2.68% last session

End-of-day data · close of 2026-09-11

Mildly bearish0 bullish · 2 bearish technical signals
Consensus: Strong Buy (1.25 from 7 analysts)
To mean target: +57.0%

Market cap

$1B

Enterprise value

$2B

Trailing P/E

Forward P/E

12.3

Dividend yield

Beta

Avg volume

1M

Employees

5K

Daily Change %

2.68%

5 Days Change

-7.39%

10 Days Change

-3.34%

30 Days Change

-3.26%

60 Days Change

-6.00%

Month to Day Change

-3.09%

Year to Day Change

-39.03%

Analyst Outlook

Consensus ratingStrong Buy
Recommendation mean (1–5)1.25
Covering analysts7
Mean price target$17.57
Low price target$13.00
Upside to mean target+57.0%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)48.6
50-day MA$11.53
200-day MA
Price vs 50-day MA-0.4%
Price vs 200-day MA
MACD histogram-0.09
Volume vs 3-month avg1.1×
52w low $6.7752w high $18.53

Analyst sentiment over time — LMRI

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-08-28

Latest call per bank · past 12 months

Barclays

Overweight

$13.00

+16.2% vs price
▲ raised from $9.00Maintains · 2026-08-28

Wells Fargo

Overweight

$22.00

+96.6% vs price
▲ raised from $0.00Initiates · 2026-01-05

Deutsche Bank

Buy

$22.00

+96.6% vs price
▲ raised from $0.00Initiates · 2026-01-05

Jefferies

Buy

$23.00

+105.5% vs price
▲ raised from $0.00Initiates · 2026-01-05

Recent rating actions

DateFirmActionRatingPrice target
2026-08-28BarclaysMaintainsOverweight$9.00 $13.00
2026-05-20BarclaysMaintainsOverweight$15.00 $9.00
2026-04-14BarclaysMaintainsOverweight$23.00 $15.00
2026-02-09Raymond JamesUpgradeOutperformStrong Buy$0.00 $23.00
2026-01-05Raymond JamesInitiatesOutperform$0.00 $23.00
2026-01-05BarclaysInitiatesOverweight$0.00 $23.00
2026-01-05Wells FargoInitiatesOverweight$0.00 $22.00
2026-01-05William BlairInitiatesOutperform$0.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-09-11

  • RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 0.3% below the 50-day MA ($11.53).
  • MACD (12,26,9): MACD histogram is negative (-0.09) — short-term momentum is fading.
  • 52-week range: Price sits between the 52-week low ($6.77) and high ($18.53).

LMRI Price Chart

Loading chart for LMRI

Fundamentals

Revenue (TTM)$1.0B
EBITDA$0M
Free cash flow
Operating cash flow$0M
Book value / share$6.40
Net Debt / EBITDA11.6
WACC
Revenue growth5.00%
Earnings growth

About Lumexa Imaging Holdings, Inc.

Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company provides outpatient medical imaging services, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) services, as well as X-ray, ultrasound, and mammography diagnostic and screening imaging services. Lumexa Imaging Holdings, Inc. was founded in 2018 and is based in Raleigh, North Carolina.

More in Medical Devices

Screen LMRI against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.